Not only in K-RAS-activated lung cancers, but in almost all other malignancies, clinical responses have been yielded through the application of targeted therapies that inhibit activated oncogenes, but despite the application of these therapies, tumor recurrence has eventually resulted [42,43]. The gene discussed is KRAS; the disease is neoplasm.